Welcome ...

D-MoZone is the place to find out what’s new with pianist/composer/educator Diane Moser. Keep an eye on this blog for updates on music, health, gigs, fundraisers, random thoughts and all things D-Mo. And please keep sending your thoughts, good wishes and comments this way—they’re always needed and always appreciated.

Tuesday, June 22, 2010

Interesting article about Novarits-Gleevec-patents and India

Novartis is trying to get a patent for Gleevec in India...
On May 19, 2006, Novartis had filed seven cases in the court, against the government, Cancer Patients Aid Association and generic manufacturers, challenging the rejection of its Gleevec patent application.

Gleevec is used to treat chronic myeloid leukemia, a life threatening form of cancer. It is a $2.2 billion drug, posting double-digit growth figures.

The drug helps in prolonging the life of cancer patients. Several Indian pharma firms like Natco, Cipla, Ranbaxy and Hetero produce the generic equivalent.

While Gleevec sells for around Rs 1.2 lakh per patient per month, a generic drug costs Rs 9,000 per patient per month.

I didn't even know there was a generic version out there-but probably not available here in the states.